Financial Reports Latest Updates Industry Maps Economic Calendar

Celldex Therapeutics, Inc. (CLDX) Annual Reports

Q: Where can I read Celldex Therapeutics, Inc. (CLDX) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Celldex Therapeutics, Inc. is listed on Nasdaq, classified by the SEC under In Vitro & In Vivo Diagnostic Substances (SIC 2835). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 744218 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$22,000	$730,000	-97.0%
Operating income	$-80.6M	$-63.9M	-26.3%
Net income	$-73.5M	$-56.6M	-29.9%
EPS (diluted)	$-0.94	$-0.85	-10.6%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 0.02 mn Net income -73.5 mn

Show table：Income statement

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	15.2	2.95	2.41	37.7	2.52	1.95	2.36	2.43	2.43	2.01	3.11	3.65	2.41	0.1	0.98	0.62	0.42	0.59	1.10	1.48	0.49	2.18	1.03	1.79	1.30	1.39	2.22	1.87	1.53	3.83	3.92	3.46	4.07	2.76	0.94	1.76	1.43	0.72	0.55	0.89	2.73	0.24	0.67	3.79	0.69	3.48	0.15	0.33	0.17	0.16	0.41	1.61	0.97	0.27	1.52	4.13	0.16	2.50	3.19	1.18	0.7	0.73	0	0.12	0.02	0.02
Operating income	-36.9	-9.29	-8.88	21.1	-9.66	-9.88	-11.5	-12.4	-13.3	-13.5	-14.8	-16.6	-17.4	-18.7	-23.3	-22.1	-31.5	-28.6	-30.3	-32.0	-31.0	-32.8	-32.4	-33.4	-35.7	-32.4	-30.0	-34.9	-35.1	-28.9	-32.0	-25.5	-120	-16.9	-7.76	-12.1	-17.9	-12.3	-11.8	-13.0	-12.9	-11.4	-14.3	-24.8	-16.6	-13.4	-20.8	-20.3	-23.3	-36.4	-27.7	-27.9	-32.5	-33.2	-41.2	-47.6	-40.6	-46.3	-52.1	-56.0	-62.7	-63.9	-73.6	-87.2	-84.4	-80.6
Net income	—	-9.52	—	—	—	-10.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-70.5	—	—	—	-112	—	—	—	-141	-32.8	-35.8	-42.1	-47.1	-53.8	-56.6	-67.0	-81.3	-78.7	-73.5

Balance sheet

Quarterly · In mn (USD)

Total assets 782 mn Total liabilities 67.8 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	63.0	—	73.3	64.4	54.7	94.2	80.4	78.8	85.1	184	156	140	305	277	256	230	205	364	340	309	295	261	229	210	196	173	160	147	145	131	120	111	99.1	88.8	84.4	75.1	66.7	55.9	209	203	198	182	168	427	411	391	368	335	318	290	265	246	432	835	812	779	747	694	648	604	535	459	725
Total assets	—	—	—	110	—	118	108	98.0	137	122	120	126	224	196	181	347	319	298	272	248	408	383	353	338	302	271	252	383	360	346	319	316	191	178	168	156	148	142	132	123	113	261	256	236	219	205	460	445	424	403	369	353	325	299	280	466	869	846	823	792	739	692	648	583	511	782
Current liabilities	—	—	—	20.2	—	10.4	10.8	14.3	12.6	12.6	15.1	17.7	18.3	12.5	16.8	20.4	19.5	21.2	21.6	24.5	21.1	26.7	23.6	30.2	25.3	20.0	18.6	35.2	27.0	28.8	24.9	27.7	24.0	20.0	16.9	12.6	12.0	11.5	11.9	11.6	10.9	10.8	12.2	14.2	17.0	14.5	14.2	16.5	14.6	29.9	16.3	18.6	15.2	15.7	27.8	31.1	26.3	27.7	32.1	39.5	32.0	33.0	46.5	51.0	51.5	61.3
Total liabilities	—	—	—	34.7	—	26.5	27.8	29.3	28.9	27.6	28.8	29.8	29.4	19.1	24.2	27.3	26.9	32.3	32.3	36.4	32.1	37.3	34.0	47.5	41.9	36.5	34.9	118	112	115	100	79.3	57.3	50.3	40.1	31.8	34.9	32.6	30.5	28.9	28.8	23.0	25.8	26.5	24.9	22.3	23.5	25.2	25.9	37.9	23.8	26.5	21.8	21.8	33.5	36.5	30.2	31.9	37.3	45.3	36.5	37.0	50.1	55.8	55.0	67.8
Equity	73.8	—	—	75.3	—	92.0	80.7	68.7	108	94.5	91.0	95.8	195	177	157	320	292	265	239	212	376	346	319	290	260	235	217	265	248	231	219	236	134	128	128	124	113	110	101	94.0	83.7	238	230	209	194	182	437	419	398	365	345	326	303	278	247	429	839	814	786	747	703	655	598	527	456	715

Cash flow

Quarterly · In mn (USD)

Operating -57.4 mn Investing -256 mn Financing 325 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-29.9	-16.6	-7.74	-6.01	-8.86	-9.36	-8.06	-9.37	-13.6	-12.0	-10.9	-13.3	-17.2	-18.1	-17.4	-15.0	-31.9	-20.9	-26.6	-22.2	-32.6	-24.8	-27.8	-13.7	-34.9	-33.8	-23.9	-20.4	-35.3	-20.8	-24.4	-19.5	-28.0	-17.4	-14.4	-15.4	-13.2	-11.0	-11.1	-11.0	-12.1	-11.2	-11.9	-5.21	-18.1	-11.9	-16.4	-14.5	-24.5	-22.2	-35.2	-21.8	-28.6	-27.2	-19.0	-32.5	-40.6	-29.3	-55.3	-32.5	-54.4	-44.0	-48.6	-63.9	-65.6	-57.4
Investing	45.1	-25.8	2.08	7.51	5.27	-25.8	10.3	8.04	-27.5	9.08	5.99	-4.54	-46.6	-22.6	5.56	-13.8	-81.3	4.60	18.0	17.7	-65.0	-16.2	12.3	18.7	25.5	0.67	14.9	27.8	22.4	35.8	1.67	-13.4	15.5	13.2	-2.22	3.35	16.3	-7.96	5.52	3.22	22.0	-109	-42.5	30.9	43.5	-13.9	-227	-18.9	10.4	25.3	23.1	31.2	52.6	1.16	11.7	-171	-315	-46.7	47.8	24.1	43.0	49.9	60.9	55.4	72.1	-256
Financing	-2.46	0.52	0.33	9.96	-7.55	35.9	-0.02	0.13	51.9	-1.31	9.58	19.6	115	-9.09	0.62	184	0.7	0.15	0.3	0.01	192	0.34	0.74	0.32	0.28	2.62	8.30	3.28	12.9	8.67	11.3	18.5	12.1	8.27	5.54	3.57	4.16	7.21	2.46	2.42	1.64	165	4.49	0.04	0.07	-0.02	272	0.43	0.3	0.07	2.31	1.40	0.69	0.13	0.26	217	436	3.71	1.24	0.39	0.2	0.06	0.77	1.35	0.33	325
Cash at period end	57.0	15.2	9.83	21.3	10.1	10.8	13.1	11.9	22.8	18.6	23.2	24.9	75.6	25.9	14.6	169	56.9	40.8	32.5	28.0	122	81.6	66.8	72.1	63.0	32.5	31.7	42.5	42.5	66.2	54.7	40.3	39.8	43.9	32.8	24.3	31.5	19.7	16.6	11.2	22.7	68.0	18.1	43.8	69.3	43.5	72.2	39.1	25.3	28.4	18.6	29.4	54.1	28.2	21.1	34.8	115	42.7	36.4	28.4	17.1	23.0	36.0	28.9	35.7	47.5

Profitability

Quarterly · %

Operating margin -366468.2% Net margin -334104.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	-242.8%	-314.7%	-368.7%	56.0%	-383.9%	-506.2%	-485.7%	-509.0%	-546.2%	-671.4%	-473.9%	-453.8%	-720.8%	-19235.0%	-2374.4%	-3566.8%	-7569.5%	-4822.5%	-2755.9%	-2170.0%	-6374.7%	-1503.7%	-3155.1%	-1868.0%	-2740.1%	-2330.2%	-1351.0%	-1859.8%	-2288.9%	-755.5%	-814.5%	-738.6%	-2941.9%	-610.7%	-825.1%	-687.2%	-1259.0%	-1714.3%	-2169.2%	-1464.4%	-471.7%	-4815.7%	-2147.0%	-654.5%	-2429.1%	-386.2%	-13610.5%	-6089.8%	-13366.1%	-22328.8%	-6804.9%	-1728.8%	-3357.9%	-12389.9%	-2718.5%	-1152.9%	-26030.8%	-1854.2%	-1633.5%	-4768.3%	-9027.2%	-8747.5%	—	-72027.3%	-562900.0%	-366468.2%
Net margin	—	-322.8%	—	—	—	-524.4%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-21111.1%	—	—	—	-6963.7%	—	—	—	-3423.6%	-21030.8%	-1434.8%	-1320.0%	-4007.8%	-7740.4%	-7753.4%	—	-67204.1%	-524566.7%	-334104.5%

Returns & leverage

Quarterly · %

ROE -43.9% ROA -40.8% Debt ratio 8.7%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-48.9%	-26.8%	-23.2%	-27.2%	-32.4%	-40.6%	-48.9%	-43.9%
ROA	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-45.7%	-25.1%	-22.2%	-26.0%	-30.5%	-37.6%	-45.4%	-40.8%
Debt ratio	—	—	—	31.6%	—	22.3%	25.6%	29.9%	21.1%	22.6%	24.1%	23.7%	13.1%	9.8%	13.4%	7.9%	8.4%	10.8%	11.9%	14.7%	7.9%	9.7%	9.6%	14.1%	13.9%	13.5%	13.8%	30.8%	31.2%	33.1%	31.4%	25.1%	29.9%	28.2%	23.9%	20.4%	23.6%	22.9%	23.1%	23.5%	25.6%	8.8%	10.1%	11.2%	11.4%	10.9%	5.1%	5.7%	6.1%	9.4%	6.5%	7.5%	6.7%	7.3%	12.0%	7.8%	3.5%	3.8%	4.5%	5.7%	4.9%	5.3%	7.7%	9.6%	10.8%	8.7%

EPS

Quarterly · US$

EPS US$-0.94

Show table：EPS

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-3.51	—	—	—	-2.02	-0.42	-0.34	-0.45	-0.43	-0.49	-0.77	-0.57	-0.57	-0.62	-0.65	-0.81	-0.84	-0.56	-0.54	-0.64	-0.71	-0.81	-0.85	-1.01	-1.23	-1.18	-0.94

Revenue & profit

Year-to-date · In mn (USD)

Revenue 0.04 mn Net income -152 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 782 mn Total liabilities 67.8 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -123 mn Investing -183 mn Financing 325 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -446102.7% Net margin -411318.9%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -43.9% ROA -40.8% Debt ratio 8.7%

EPS

Year-to-date · US$

EPS US$-2.12

Revenue & profit

Annual · In mn (USD)

Revenue 1.55 mn Net income -259 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	9.26	11.2	4.11	3.59	5.48	6.79	12.7	9.54	3.57	7.42	4.65	2.36	6.88	7.02	1.55
Operating income	-43.4	-58.1	-81.4	-122	-130	-133	-122	-156	-55.0	-63.4	-71.2	-115	-155	-195	-287
Net income	—	—	—	—	—	—	—	—	—	—	—	—	—	-158	-259

Balance sheet

Annual · In mn (USD)

Total assets 583 mn Total liabilities 55.8 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	54.7	85.1	305	205	295	196	145	99.1	66.7	198	411	318	432	747	535
Total assets	98.0	126	347	248	338	383	316	156	123	236	445	353	466	792	583
Current liabilities	14.3	17.7	20.4	24.5	30.2	35.2	27.7	12.6	11.6	14.2	16.5	18.6	31.1	39.5	51.0
Total liabilities	29.3	29.8	27.3	36.4	47.5	118	79.3	31.8	28.9	26.5	25.2	26.5	36.5	45.3	55.8
Equity	68.7	95.8	320	212	290	265	236	124	94.0	209	419	326	429	747	527

Cash flow

Annual · In mn (USD)

Operating -211 mn Investing 209 mn Financing 2.39 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-35.7	-49.8	-67.7	-102	-98.9	-113	-99.9	-75.2	-46.4	-40.4	-60.9	-104	-107	-158	-211
Investing	-2.15	-17.0	-77.4	-41.0	-50.2	68.9	46.5	29.8	17.1	-98.2	-216	89.9	-106	-290	209
Financing	28.4	79.8	290	1.17	193	14.5	51.3	29.4	16.3	171	272	4.08	218	441	2.39
Cash at period end	11.9	24.9	169	28.0	72.1	42.5	40.3	24.3	11.2	43.8	39.1	29.4	34.8	28.4	28.9

Profitability

Annual · %

Operating margin -18587.7% Net margin -16737.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	-468.5%	-518.5%	-1981.1%	-3414.1%	-2363.9%	-1958.7%	-953.7%	-1640.5%	-1540.2%	-854.1%	-1531.5%	-4889.0%	-2245.3%	-2778.9%	-18587.7%
Net margin	—	—	—	—	—	—	—	—	—	—	—	—	—	-2248.8%	-16737.2%

Returns & leverage

Annual · %

ROE -40.6% ROA -37.6% Debt ratio 9.6%

Show table：Returns & leverage

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	—	—	—	—	—	—	—	—	—	—	—	—	-26.8%	-40.6%
ROA	—	—	—	—	—	—	—	—	—	—	—	—	—	-25.1%	-37.6%
Debt ratio	29.9%	23.7%	7.9%	14.7%	14.1%	30.8%	25.1%	20.4%	23.5%	11.2%	5.7%	7.5%	7.8%	5.7%	9.6%

EPS

Annual · US$

EPS US$-3.90

Show table：EPS

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	—	—	—	—	-1.64	-2.40	-2.92	-2.45	-3.90

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Celldex Therapeutics, Inc. (CLDX) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.